<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2830">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04504032</url>
  </required_header>
  <id_info>
    <org_study_id>Gates MRI - COD-01-T01-01</org_study_id>
    <nct_id>NCT04504032</nct_id>
  </id_info>
  <brief_title>A Trial to Evaluate Safety and Efficacy of Rivaroxaban (COVID-19)</brief_title>
  <official_title>A Randomized, Controlled, Phase 2b Study to Evaluate Safety and Efficacy of Rivaroxaban (Xarelto®) for High Risk People With Mild COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bill &amp; Melinda Gates Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bill &amp; Melinda Gates Medical Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess safety and clinical efficacy of rivaroxaban in people&#xD;
      with mild Coronavirus Disease 2019 who are at increased risk of disease progression.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2, 2020</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Grade 3 or Grade 4 Adverse Events (AEs)</measure>
    <time_frame>Up to approximately 35 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With AEs Leading to Study Discontinuation</measure>
    <time_frame>Up to approximately 35 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to approximately 35 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Participants With Disease Progression</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>Disease progression is defined as the proportion of participants who progress to moderate or severe disease category or higher (Gates Medical Research Institute ordinal scale ≥3). The assessments will be performed using Gates Medical Research Institute ordinal scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median Time to Disease Resolution</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>Time to disease resolution is defined as symptoms resolution (new onset Coronavirus Disease 2019 [COVID-19] symptoms resolved, and pre-existing symptoms returned to baseline) with viral clearance (two consecutive negative diagnostic tests) through Day 28. Baseline refers to health status prior to contracting new onset COVID-19 symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Time to Disease Resolution</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>Time to disease resolution is defined as symptoms resolution only (new onset COVID-19 symptoms resolved, and preexisting symptoms returned to baseline) through Day 28. Baseline refers to health status prior to contracting new onset COVID-19 symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Disease Progression</measure>
    <time_frame>Days 8, 14, and 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Who Achieve Disease Resolution</measure>
    <time_frame>Days 8, 14, 21, and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Gates Medical Research Institute Ordinal Scale Score</measure>
    <time_frame>Days 8, 14, 21, and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Gates Medical Research Institute Ordinal Scale Score</measure>
    <time_frame>Days 8, 14, 21, and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean World Health Organization Ordinal Scale Score</measure>
    <time_frame>Days 8, 14, 21, and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in World Health Organization Ordinal Scale Score</measure>
    <time_frame>Days 8, 14, 21, and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Hospitalization</measure>
    <time_frame>Days 8, 14, 21, and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days of Hospitalization</measure>
    <time_frame>Days 8, 14, 21, and 28</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>Participants will receive Rivaroxaban 10 milligram (mg) tablet by mouth, once daily for 21 days</description>
    <arm_group_label>Rivaroxaban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive placebo (multi-vitamin supplement) tablet by mouth, once daily for 21 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants must be at high-risk for Coronavirus disease 2019 (COVID-19) disease&#xD;
             progression by fulfilling at least one of the following criteria at screening:&#xD;
&#xD;
               -  Presence of chronic pulmonary disease, chronic obstructive pulmonary disease&#xD;
                  (COPD), pulmonary hypertension&#xD;
&#xD;
               -  Diabetes mellitus (type 1 or type 2), requiring oral medication or insulin for&#xD;
                  treatment&#xD;
&#xD;
               -  Hypertension, requiring at least one oral medication for treatment&#xD;
&#xD;
               -  Immunocompromised status due to disease (e.g., those living with human&#xD;
                  immunodeficiency virus with a cluster of differentiation 4 [CD4] T-cell count of&#xD;
                  &lt;200 per cubic millimeter [mm^3])&#xD;
&#xD;
               -  Immunocompromised status due to medication (e.g., taking 20 milligram [mg] or&#xD;
                  more of prednisone equivalents a day, anti-inflammatory monoclonal antibody&#xD;
                  therapies, cancer therapies)&#xD;
&#xD;
               -  Any chronic disease that is associated with high risk for severe COVID in the&#xD;
                  opinion of the site investigator&#xD;
&#xD;
               -  Body mass index ≥35 Kilogram per square meter (kg/m^2) (based on self-reported&#xD;
                  weight and height).&#xD;
&#xD;
          -  Documented Severe Acute Respiratory Syndrome Coronavirus 2 positive diagnostic test of&#xD;
             ≤7 days at the time of screening&#xD;
&#xD;
          -  Symptomatic for COVID-19 for ≤72 hours at the time of screening (defined as having at&#xD;
             least 2 of the following symptoms of COVID-19 that is of new onset or has worsened&#xD;
             from baseline, and include fever, chills, myalgia, arthralgia, headache, fatigue,&#xD;
             cough, sore throat, nasal congestion, anosmia, ageusia, nausea, vomiting, or diarrhea.&#xD;
             If only two symptoms are present, they cannot both be anosmia and ageusia)&#xD;
&#xD;
          -  Capable of giving informed consent, which includes compliance with the requirements&#xD;
             and restrictions listed in the inform consent form and in this protocol&#xD;
&#xD;
          -  Agree to participate in all remote, in-person or home visits as required in the&#xD;
             protocol and provide updated contact information as necessary.&#xD;
&#xD;
          -  Female of childbearing potential must agree to practice adequate contraception during&#xD;
             the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Participants are excluded from the study if any of the following criteria apply:&#xD;
&#xD;
          -  Currently hospitalized or under immediate consideration for hospitalization at&#xD;
             screening and Day 1&#xD;
&#xD;
          -  Have new onset shortness of breath or increased shortness of breath from pre-COVID-19&#xD;
             (for people with known COPD) at screening and Day 1&#xD;
&#xD;
          -  Hypoxemia (oxygen saturation &lt;94% in ambient air or oxygen saturation below&#xD;
             pre-COVID-19 level for people with known COPD) at Day 1&#xD;
&#xD;
          -  Require supplemental oxygen (new requirement or increase in requirement from&#xD;
             pre-COVID-19 condition) at screening and Day 1&#xD;
&#xD;
          -  Have a history of (in the past 3 months) or current active pathological bleeding&#xD;
&#xD;
          -  Have a history of hemorrhagic stroke or intracranial hemorrhage&#xD;
&#xD;
          -  Have a recent severe head trauma within 30 days which includes concussion, skull&#xD;
             fracture or hospitalization for head injury&#xD;
&#xD;
          -  Have known intracranial neoplasm, cerebral metastases, arteriovenous malformation or&#xD;
             aneurysm&#xD;
&#xD;
          -  Have history of pregnancy-related hemorrhage&#xD;
&#xD;
          -  Have active gastroduodenal ulcer or other gastrointestinal bleeding diagnosed in the&#xD;
             past 3 months&#xD;
&#xD;
          -  Currently are in a hemodynamically unstable state&#xD;
&#xD;
          -  Currently require thrombolysis or pulmonary embolectomy&#xD;
&#xD;
          -  Have history of severe hypersensitivity reaction to Xarelto®&#xD;
&#xD;
          -  Currently have a prosthetic heart valve&#xD;
&#xD;
          -  Have known diagnosis of triple positive antiphospholipid syndrome&#xD;
&#xD;
          -  Have known diagnosis of chronic kidney disease (stage IV or receiving dialysis)&#xD;
&#xD;
          -  Have a history of thrombocytopenia or known platelet count &lt;100,000 cells/mm^3&#xD;
&#xD;
          -  Have history of bronchiectasis and pulmonary cavitation&#xD;
&#xD;
          -  Have active cancer (e.g, receiving chemotherapy or treatment for complication of the&#xD;
             active cancer)&#xD;
&#xD;
          -  Had epidural or neuraxial anesthesia or spinal puncture in the past 2 weeks and plan&#xD;
             to undergo these procedures during the study&#xD;
&#xD;
          -  Had surgery in the past 4 weeks or plan to undergo surgery during the study&#xD;
&#xD;
          -  Currently is pregnant or plans to become pregnant&#xD;
&#xD;
          -  Currently is breastfeeding&#xD;
&#xD;
          -  Share household with an enrolled participant in this study&#xD;
&#xD;
          -  Co-enrollment in any clinical trial that includes prohibited procedures (spinal&#xD;
             puncture or surgery) or that includes treatments within the same drug class as&#xD;
             rivaroxaban or treatments for which co-administration with rivaroxaban are prohibited.&#xD;
             Note that any co-enrollment other than this requires approval by the Sponsor. For any&#xD;
             coenrolled study, the total volume of blood samples collected across the studies&#xD;
             should not exceed 275 milliliters (mL) in 4 weeks.&#xD;
&#xD;
          -  Currently using and plan to use the following medications during the study&#xD;
&#xD;
               -  Rivaroxaban or drugs in the same class&#xD;
&#xD;
               -  Dual anti-platelets therapy&#xD;
&#xD;
               -  Other anticoagulants&#xD;
&#xD;
               -  Combined Permeability glycoprotein (P-gp) and cytochrome CYP3A inhibitors and&#xD;
                  inducers&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GatesMRI</last_name>
    <role>Study Director</role>
    <affiliation>Bill &amp; Melinda Gates Medical Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gates MRI</last_name>
    <phone>+1 857 702 2108</phone>
    <email>clinical.trials@gatesmri.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gates MRI (Toll Free Number)</last_name>
    <phone>+1 866 789 5767</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Woodland Research Northwest LLC - ERG - PPDS</name>
      <address>
        <city>Rogers</city>
        <state>Arkansas</state>
        <zip>72758</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Science 37, Inc</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90094</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Allergy and Asthma Medical Group and Research Center - CRN - PPDS</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Invesclinic, LLC</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Advanced Pulmonary Research Institute</name>
      <address>
        <city>Loxahatchee Groves</city>
        <state>Florida</state>
        <zip>33470</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>LCC Medical Research - Miami - BTC - PPDS</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Adult Medicine of Lake County</name>
      <address>
        <city>Mount Dora</city>
        <state>Florida</state>
        <zip>32757</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Providea Health Partners LLC</name>
      <address>
        <city>Evergreen Park</city>
        <state>Illinois</state>
        <zip>60805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute, Inc - CRN - PPDS</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55402</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Encompass Care</name>
      <address>
        <city>North Las Vegas</city>
        <state>Nevada</state>
        <zip>89086</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Riverside Medical Group - Circuit- PPDS</name>
      <address>
        <city>Secaucus</city>
        <state>New Jersey</state>
        <zip>07094</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NYC Health + Hospitals/Lincoln</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10451</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Elmhurst Hospital Center</name>
      <address>
        <city>Elmhurst</city>
        <state>New York</state>
        <zip>11373</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Harlem Hospital Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Premier Family Physicians - Austin - Hunt - PPDS</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78735</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Village Health Partners - Plano - Hunt - PPDS</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>South Texas Allergy and Asthma Medical Professionals</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Boundary House Medical Centre</name>
      <address>
        <city>Sale</city>
        <state>Cheshire</state>
        <zip>M33 2RH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>St Mary's Hospital - PPDS</name>
      <address>
        <city>London</city>
        <state>City Of London</state>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <zip>NW3 2Q</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 5, 2020</study_first_submitted>
  <study_first_submitted_qc>August 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2020</study_first_posted>
  <last_update_submitted>January 28, 2021</last_update_submitted>
  <last_update_submitted_qc>January 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rivaroxaban</keyword>
  <keyword>Xarelto</keyword>
  <keyword>Coronavirus</keyword>
  <keyword>COVID-19</keyword>
  <keyword>Coronavirus disease 2019</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

